BACKGROUND: We determined the expression of forkhead box Q1 (FoxQ1), E-cadherin (E-cad), Mucin 1 (MUC1), vimentin (VIM) and S100 calcium binding protein A4 (S100A4), all epithelial-mesenchymal transition (EMT) indicator proteins in non-small cell lung cancer (NSCLC) tissue samples. We also investigated the relationship between these five proteins expression and other clinicopathologic factors in NSCLC. Finally, we assessed the potential value of these markers as prognostic indicators of survival in NSCLC's patients. METHODS: Quantitative real-time PCR and immunohistochemistry were used to characterize the expression of the FoxQ1 mRNA and protein in NSCLC. Expression of transcripts and translated products for the other four EMT indicator proteins was assessed by immunohistochemistry in the same clinical NSCLC samples. RESULTS: FoxQ1 mRNA and protein were up-regulated in NSCLC compared with normal tissues (P = 0.015 and P<0.001, respectively). Expression of FoxQ1 in adenocarcinoma was higher than in squamous cell carcinoma (P = 0.005), and high expression of FoxQ1 correlated with loss of E-cad expression (P = 0.012), and anomalous positivity of VIM (P = 0.024) and S100A4 (P = 0.004). Additional survival analysis showed that high expression of FoxQ1 (P = 0.047) and E-cad (P = 0.021) were independent prognostic factors. CONCLUSION: FoxQ1 maybe plays a specific role in the EMT of NSCLC, and could be used as a prognostic factor for NSCLC.
BACKGROUND: We determined the expression of forkhead box Q1 (FoxQ1), E-cadherin (E-cad), Mucin 1 (MUC1), vimentin (VIM) and S100 calcium binding protein A4 (S100A4), all epithelial-mesenchymal transition (EMT) indicator proteins in non-small cell lung cancer (NSCLC) tissue samples. We also investigated the relationship between these five proteins expression and other clinicopathologic factors in NSCLC. Finally, we assessed the potential value of these markers as prognostic indicators of survival in NSCLC'spatients. METHODS: Quantitative real-time PCR and immunohistochemistry were used to characterize the expression of the FoxQ1 mRNA and protein in NSCLC. Expression of transcripts and translated products for the other four EMT indicator proteins was assessed by immunohistochemistry in the same clinical NSCLC samples. RESULTS:FoxQ1 mRNA and protein were up-regulated in NSCLC compared with normal tissues (P = 0.015 and P<0.001, respectively). Expression of FoxQ1 in adenocarcinoma was higher than in squamous cell carcinoma (P = 0.005), and high expression of FoxQ1 correlated with loss of E-cad expression (P = 0.012), and anomalous positivity of VIM (P = 0.024) and S100A4 (P = 0.004). Additional survival analysis showed that high expression of FoxQ1 (P = 0.047) and E-cad (P = 0.021) were independent prognostic factors. CONCLUSION:FoxQ1 maybe plays a specific role in the EMT of NSCLC, and could be used as a prognostic factor for NSCLC.
Authors: A Feuerborn; P K Srivastava; S Küffer; W A Grandy; T P Sijmonsma; N Gretz; B Brors; H-J Gröne Journal: J Cell Physiol Date: 2011-03 Impact factor: 6.384
Authors: Philip T Cagle; Timothy C Allen; Sanja Dacic; Mary Beth Beasley; Alain C Borczuk; Lucian R Chirieac; Rodolfo Laucirica; Jae Y Ro; Keith M Kerr Journal: Arch Pathol Lab Med Date: 2011-01 Impact factor: 5.534
Authors: Aïda Ghoul; Maria Serova; Lucile Astorgues-Xerri; Ivan Bieche; Guilhem Bousquet; Mariana Varna; Michel Vidaud; Edelmira Phillips; Sophie Weill; Karim A Benhadji; François Lokiec; Esteban Cvitkovic; Sandrine Faivre; Eric Raymond Journal: Cancer Res Date: 2009-05-05 Impact factor: 12.701
Authors: Archis Bagati; Anna Bianchi-Smiraglia; Sudha Moparthy; Kateryna Kolesnikova; Emily E Fink; Masha Kolesnikova; Matthew V Roll; Peter Jowdy; David W Wolff; Anthony Polechetti; Dong Hyun Yun; Brittany C Lipchick; Leslie M Paul; Brian Wrazen; Kalyana Moparthy; Shaila Mudambi; Galina E Morozevich; Sofia G Georgieva; Jianmin Wang; Gal Shafirstein; Song Liu; Eugene S Kandel; Albert E Berman; Neil F Box; Gyorgy Paragh; Mikhail A Nikiforov Journal: Cell Death Differ Date: 2018-02-20 Impact factor: 15.828